CTLA-4 +49A/G Polymorphism Increases the Susceptibility to Bladder Cancer in Chinese Han Participants: A Case-Control Study

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2020 Dec 18

PMID 33335608

Citations 4

Authors

Fei Mao

Xiao-Bing Niu

Shuo Gu

Lu Ji

Bing-Jian Wei

Heng-Bing Wang

Affiliations

Soon will be listed here.

Abstract

Cytotoxic T cell antigen-4 (CTLA-4) is reportedly involved in the development of bladder cancer (BC). This research was designed to address the potential link between the +49A/G polymorphism in CTLA-4 gene and BC susceptibility. In total, 355 BC cases and 435 match controls from Chinese Han individuals were included eventually. The PCR-RFLR method was utilized to screen for this polymorphism. The +49A/G polymorphism was shown to increase the risk of BC. Subgroup analyses showed that this polymorphism was linked to an increased susceptibility to BC among individuals aged < 60 years, smokers and drinkers. Additionally, this polymorphism significantly correlated with tumor node metastasis and tumor size (≥3 cm). To sum up, this study reveals that the CTLA-4 +49A/G polymorphism could increase the risk of BC in Chinese Han people. Further large cohort studies with enough sample sizes are urgently warranted to verify the findings of this present study.

Citing Articles

The Relationship Between CTLA-4 (-318 C/T) Polymorphism and Urothelial Cancer Carcinogenesis in Japanese Patients.

Damayanti P, Hlaing S, Aung K, Tsukino H, Hinoura T, Kuroda Y Cureus. 2023; 15(10):e48068.

PMID: 38046481 PMC: 10689122. DOI: 10.7759/cureus.48068.

The C55A Single Nucleotide Polymorphism in Gene, a New Possible Biomarker in Thyroid Autoimmune Pathology Such as Hashimoto's Thyroiditis.

Chiorean A, Vica M, Balici S, Nicula G, Racataianu N, Bordea M Diagnostics (Basel). 2023; 13(15).

PMID: 37568880 PMC: 10417055. DOI: 10.3390/diagnostics13152517.

A novel 17 apoptosis-related genes signature could predict overall survival for bladder cancer and its associations with immune infiltration.

Wang Y, Cheng H, Zeng T, Chen S, Xing Q, Zhu B Heliyon. 2022; 8(11):e11343.

PMID: 36387445 PMC: 9647203. DOI: 10.1016/j.heliyon.2022.e11343.

Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.

Wan H, Zhou H, Feng Y, Chen Y, Zhu L, Mi Y Front Oncol. 2022; 12:878507.

PMID: 35600409 PMC: 9114750. DOI: 10.3389/fonc.2022.878507.

References

Fernandez M, Brausi M, Clark P, Cookson M, Grossman H, Khochikar M . Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2018; 37(1):3-13. DOI: 10.1007/s00345-018-2436-y. View

Zhang W, Shi L, Zhao Z, Du P, Ye X, Li D . Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019; 83(5):911-920. DOI: 10.1007/s00280-019-03800-x. View

Wang M, Li Z, Chu H, Lv Q, Ye D, Ding Q . Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3. Cancer Res. 2016; 76(11):3277-84. DOI: 10.1158/0008-5472.CAN-15-2564. View

Bhanvadia S . Bladder Cancer Survivorship. Curr Urol Rep. 2018; 19(12):111. DOI: 10.1007/s11934-018-0860-6. View

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Bilbao-Aldaiturriaga N, Patino-Garcia A, Martin-Guerrero I, Garcia-Orad A . Cytotoxic T lymphocyte-associated antigen 4 rs231775 polymorphism and osteosarcoma. Neoplasma. 2017; 64(2):299-304. DOI: 10.4149/neo_2017_218. View

Moschini M, DAndrea D, Korn S, Irmak Y, Soria F, Comperat E . Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017; 14(11):651-668. DOI: 10.1038/nrurol.2017.125. View

Fang M, Huang W, Mo D, Zhao W, Huang R . Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies. Cell Physiol Biochem. 2018; 47(1):414-427. DOI: 10.1159/000489953. View

Zigeuner R . Bladder cancer in 2016: News in diagnosis, treatment, and risk group assessment. Nat Rev Urol. 2017; 14(2):74-76. DOI: 10.1038/nrurol.2016.264. View

10.

Mao F, Niu X, Gu S, Ji L, Wei B, Wang H . The association between matrix metalloproteinase-7 genetic variant and bladder cancer risk in a Chinese Han population. Clin Exp Med. 2019; 19(4):565-570. DOI: 10.1007/s10238-019-00582-7. View

11.

Knowles M, Hurst C . Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2014; 15(1):25-41. DOI: 10.1038/nrc3817. View

12.

Thompson C, Allison J . The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997; 7(4):445-50. DOI: 10.1016/s1074-7613(00)80366-0. View

13.

Jaiswal P, Singh V, Mittal R . Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population. Mol Biol Rep. 2014; 41(2):799-807. DOI: 10.1007/s11033-013-2919-2. View

14.

He L, Deng T, Luo H . Association between cytotoxic T-lymphocyte antigen-4 +49A/G polymorphism and colorectal cancer risk: a meta-analysis. Int J Clin Exp Med. 2015; 8(3):3752-60. PMC: 4443105. View

15.

Wang C, Liu W, Zhao L, Dong Z . Association of cytotoxic T-lymphocyte antigen-4 + 49A/G gene polymorphism with hepatocellular carcinoma risk in Chinese. J Cancer Res Ther. 2018; 14(Supplement):S1117-S1120. DOI: 10.4103/0973-1482.203604. View

16.

van Hooren L, Sandin L, Moskalev I, Ellmark P, Dimberg A, Black P . Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2016; 47(2):385-393. DOI: 10.1002/eji.201646583. View

17.

Wang L, Su G, Zhao X, Cai Y, Cai X, Zhang J . Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk. Tumour Biol. 2013; 35(2):1139-42. DOI: 10.1007/s13277-013-1152-x. View

18.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa J . A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010; 42(11):978-84. PMC: 3049891. DOI: 10.1038/ng.687. View

19.

Davarpanah N, Yuno A, Trepel J, Apolo A . Immunotherapy: a new treatment paradigm in bladder cancer. Curr Opin Oncol. 2017; 29(3):184-195. PMC: 5526432. DOI: 10.1097/CCO.0000000000000366. View

20.

Valk E, Rudd C, Schneider H . CTLA-4 trafficking and surface expression. Trends Immunol. 2008; 29(6):272-9. PMC: 4186961. DOI: 10.1016/j.it.2008.02.011. View